Live price
SUNPHARMA · Healthcare
₹1,751.20
+11.20 (+0.64%)
Day High
₹1,767.90
Day Low
₹1,740.00
52W High
₹2,046.90
52W Low
₹1,583.70
Volume today: 15.48 L
Key fundamentals
Market cap
₹3.8 L Cr
P/E ratio
35.0x
P/B ratio
4.8x
ROE
12.5%
Debt / Equity
—
Dividend yield
0.9%
Revenue growth
—
Earnings growth
—
Live fundamentals from Yahoo Finance where available. Reference ratios may lag the latest quarterly results.
PaisaTamil Consensus
HOLDScore 63/100 · Medium confidence
Mixed signals across valuation and momentum. Existing investors may hold; new entries should wait for clarity.
12M Price Target
₹1,926
Low ₹1,716 · High ₹2,189
Analyst-style Breakdown
Strong Buy
0
Buy
3
Hold
21
Sell
0
Strong Sell
0
Derived from public market signals — price momentum, earnings trend, valuation, quality, and technical position — modelled in an analyst-style consensus format.
Signal Breakdown
Price Momentum55/100
1M -5.3%, 1Y +3.7%
Earnings Trend80/100
Latest quarter revenue ₹15.2k Cr, profit ₹2.9k Cr
Valuation62/100
P/E 35.0x vs sector median ~35x
Financial Quality65/100
ROE 12.5%, ROCE 11.8%
Technical Position48/100
Trading between 52W low 1584 and high 2047
Modelled from public market signals — not live broker analyst data. For education only; not SEBI-registered investment advice.
Price Chart
Quarterly Results
| Quarter | Revenue | Net Profit | EPS | Rev YoY | Profit YoY |
|---|---|---|---|---|---|
| Jun 2026 | ₹15.2k Cr | ₹2.9k Cr | ₹12.10 | +18.5% | +34.6% |
| Mar 2026 | ₹14.6k Cr | ₹2.7k Cr | ₹11.30 | — | — |
| Dec 2025 | ₹15.5k Cr | ₹3.4k Cr | ₹14.00 | — | — |
| Jun 2025 | ₹13.8k Cr | ₹2.3k Cr | ₹9.50 | — | — |
| Mar 2025 | ₹12.8k Cr | ₹2.1k Cr | ₹9.00 | — | — |
Reference Ratios
Market Capⓘ
₹3.8 L Cr
P/E Ratioⓘ
35.0x
P/B Ratioⓘ
4.8x
ROEⓘ
12.5%
ROCEⓘ
11.8%
Div Yieldⓘ
0.9%
Company Overview
Sun Pharma manufactures and sells generic drugs, specialty medicines, and branded formulations across India, US, and emerging markets.
Strengths
- + Strong US generic and specialty pipeline
- + India chronic therapy market leadership
- + Improving margin profile
- + Debt reduction and cash generation
Risks
- − US FDA inspection and compliance risk
- − Price erosion in US generics
- − Currency impact on US revenue
- − Patent cliff on specialty products
Latest News
No recent news articles for Sun Pharmaceutical yet. Check back after the next hourly scan.
Browse all market news →Investor Questions
Yes. Sun Pharmaceutical is a current constituent of the Nifty 50, which means it is among the 50 largest and most liquid stocks on the National Stock Exchange (NSE).